The use of new radiopharmaceutical agents in nuclear medicine allows for patient-specific strategies that leverages diagnostic techniques to provide effective targeted therapy. This relies on the use of isotope pairs for the development of imaging and therapeutic radionuclides and agents with similar chemistry and pharmacokinetic profiles. In particular, our group has developed cyclotron targetry, purification strategies and radiochemistry for radioactive first row transition metals including 43Sc and 47Sc. The goal of this work is to develop purification strategies and radiochemistry for the development of agents that incorporate the matched-pair radioisotopes of Sc which would guarantee identical chemistries and pharmacological profiles for imaging and therapy studies The radiometal isotopes of scandium have been of interest for the creation of theranostic strategies using diagnostic and therapeutic radiopharmaceuticals with identical structures. Our group has focused on the use of titanium metal and titanium oxide targets to optimize a robust strategy for the production of the diagnostic isotope, 43Sc and the therapeutic isotope 47Sc via the p,alpha reactions on titanium targets. Recent work has resulted in optimized, robust separation processes with high yields and specific activity. Preliminary studies also provide the groundwork for the development of table complexes with these isotopes for the development of 43Sc and 47Sc radiopharmaceuticals for PET imaging and targeted therapy.

Production and purification of Sc radionuclides from Ti metal and oxide targets

ACS Fall 2021

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.